Predicting the Immune Response with NeoScreen™

Are you searching for Neo-Epitopes?

Our unique NeoScreen™ Assay allows you to identify top neo-epitope candidates.

Tell me more!

It’s all about recognition

Immune recognition starts with MHC I and MHC II.

Learn why you can rely on Immunitrack’s competence in manufacturing immune reagents.

Read more


When you’re investigating the immune response, you need reagents you can rely on.

Moving Biologics Discovery Forward


Identify neo-epitopes faster.

Read more


Identify potent antigens that the patient’s immune system will respond to.

Read more

Precision Medicine

Profile patients for adoptive T-cell therapy.

Read more


Reduce the immunogenicity of therapeutic proteins. Maintain function and develop best-in-class biologics.

Read more

Immunitrack has a stellar reputation in the field of peptide-MHC manufacture. Communication was prompt and clear. Our MHC tetramers arrived within a short timeframe. This allowed us to do faster iterations on our project.

Immunologist Biotech Company, California

Novozymes Biopharma uses the FcRn from Immunitrack to develop the albumin based half-life extension platform Veltis®. We have tested a number of commercially available FcRn’s in our screening assay developed for identification of albumin variants with improved affinity for FcRn receptor and found that the biotinylated FcRn’s from Immunitrack deliver superior performance. These biotinylated FcRn’s enable a robust immobilization to Streptavidin-biosensors (Octet Red96 from Pall ForteBio) and deliver very consistent and robust data.

Birgitte Andersen Science manager, Novozymes